(Press-News.org) New data from the University of Washington's Alcohol and Drug Abuse Institute indicates increases in heroin availability, abuse and deaths across the state, particularly among young adults ages 18-29. These increases are concerning because of the high risks of overdose and contracting infectious diseases associated with heroin use.
Police drug evidence testing, particularly in 2011 and 2012, points to dramatic increases in heroin. The largest increases were outside of metropolitan areas; the number of pieces of police evidence positive for heroin totaled 842 in 2007 and increased to 2,251in 2012 statewide.
"We are hearing about heroin as a major and increasing problem from law enforcement across Washington in 2012," reports Dave Rodriguez, director of the Northwest High Intensity Drug Trafficking Areas group, a coordinating center for federal and local law enforcement.
In 2012, 64 percent of people entering publicly funded treatment for the first time were heroin users ranging in age from 18 to 29.
"Opiate addiction is a chronic disease that leads to increased hospitalizations and even death, so we want to provide a scope of interventions and treatment," said Chris Imhoff, director of the Washington State Division of Behavioral Health and Recovery in the Department of Social and Health Services. "For those who become addicted, counseling, medication-assisted treatment and recovery support are proven to save lives and reduce future healthcare costs."
Statewide, the rate of accidental deaths involving heroin and other unspecified opiates increased during the period between 2009 and 2011 compared to the previous decade. In King County, which has data through 2012, heroin- involved deaths increased substantially in 2012 due to increases in deaths among people under the age of 30. Between 1997 and 2012 in King County, almost three-quarters of drug- caused deaths involved heroin and/or a prescription-type opiate.
"All opiate overdoses are preventable and many can be reversed prior to becoming fatal if medical aid is sought, "said Dr. Daniel Lessler, the chief medical officer of Washington State's Health Care Authority. "Anyone at risk for having or anticipating an opiate overdose can be prescribed the antidote naloxone in Washington. It is intended for people at risk of an overdose whether they are taking opiate pain medicines or are dealing with opiate addictions."
"People need to be aware of the 911 Overdose Good Samaritan law that provides legal immunity from prosecution for drug possession charges to an overdose victim and anyone who seeks medical help during an overdose," said Caleb Banta-Green, author of the report and a researcher at the Alcohol and Drug Abuse Institute at the University of Washington. "We are continually increasing education and services to try to prevent fatal overdoses. The general public, as well as law enforcement and health care professionals, can learn more at http://www.stopoverdose.org."
###
For the full report on opiate trends visit http://adai.uw.edu/pubs/InfoBriefs/ADAI-IB-2013-02.pdf
Heroin availability increasing across Washington state
New data reveals rise in drug's use among young adults
2013-06-12
ELSE PRESS RELEASES FROM THIS DATE:
EULAR 2013 highlights
2013-06-12
Madrid, Spain, 12 June 2013: The launch of the European Rheumatology Research Foundation (ERRF) was today announced at EULAR 2013, the Annual Congress of the European League Against Rheumatism.
The European Rheumatology Research Foundation (ERRF) is an independent, non-profit body devoted to promoting research in rheumatic and musculoskeletal diseases (RMDs). The ERRF supports high-quality, peer-reviewed research by raising funds from commercial and non-commercial donors. The ERRF aims to support basic and applied research in order to reduce the burden of disease for ...
Significant improvements in psoriatic arthritis with ustekinumab
2013-06-12
Madrid, Spain, 12 June 2013: New PSUMMIT 2* data first presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, further demonstrate the efficacy of ustekinumab in Psoriatic Arthritis (PsA).
Anti-TNF naïve and anti-TNF-experienced patients randomised to one of two ustekinumab doses (45mg or 90mg) demonstrated significant and sustained improvements in the signs and symptoms of PsA, with favourable safety profiles.
PsA is a chronic inflammatory arthritis associated with psoriasis which significantly impacts health-related quality of life ...
Patients use OTC NSAIDs even when they have a high risk of serious side effects
2013-06-12
Madrid, Spain, 12 June 2013: A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that one in eight patients at risk of developing a serious adverse drug event (ADE) is taking over-the-counter (OTC) non-steroidal anti-inflammatory drugs (NSAIDs), often to treat a musculoskeletal complaint.
Of these high risk OTC NSAID users, over one-third had taken the medication for more than 7 days, and 3% had exceeded the maximum recommended daily dosage.
Patients were considered at high risk of a serious ADE from OTC ...
Brodalumab demonstrates significant clinical response in psoriatic arthritis
2013-06-12
Madrid, Spain, 12 June 2013: A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that treatment with brodalumab demonstrates significant clinical response and an acceptable safety profile in subjects with psoriatic arthritis (PsA).
PsA is a chronic inflammatory arthritis associated with psoriasis which significantly impacts health-related quality of life in patients, and increases risk of co-morbid cardiovascular and gastrointestinal diseases.2 Psoriasis occurs in 2-3% of the population, with PsA occurring in ...
'Fast track' approach to giant cell arteritis significantly reduces risk of blindness
2013-06-12
Madrid, Spain, 12 June 2013: A new study presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that rapid evaluation for Giant Cell Arteritis (GCA) by Color Doppler Ultrasound (CDUS) followed by immediate initiation of treatment (if required) significantly reduces permanent vision loss.
Of the patients evaluated by the ''fast track'' principle from March 2010 to December 2012, 11.1% had transient visual manifestations, and none went on to suffer from permanent visual loss.
GCA is a condition in which medium and large-size arteries, ...
CHERISH trial demonstrates efficacy of tocilizumab in juvenile idiopathic arthritis
2013-06-12
Madrid, Spain, 12 June 2013: A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism shows that tocilizumab is efficacious and leads to a sustained clinically meaningful improvement in children with polyarticular Juvenile Idiopathic Arthritis (pcJIA).
Tocilizumab is a humanized recombinant antibody, which blocks the receptors where interleukin-6 (IL-6) attaches to the surface of cells. When IL-6 is unable to attach to these cells, they are prevented from driving inflammation. Elevated serum and joint fluid IL-6 levels ...
Abatacept as effective as adalimumab in rheumatoid arthritis
2013-06-12
Madrid, Spain, 12 June 2013: Data from AMPLE presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate comparable efficacy and similar safety profiles between subcutaneous abatacept (ABA) and adalimumab (ADA).
AMPLE, the first two-year head-to-head biologics trial, was comprised of 646 biologic-naïve patients with active rheumatoid arthritis (RA) equally randomised to either ABA or ADA, with a stable dose of methotrexate (MTX). 79.2% (252 of 318) ABA patients and 74.7% (245 of 328) ADA patients completed the trial.
RA is a ...
Long-term apremilast demonstrates continued efficacy in patients with psoriatic arthritis
2013-06-12
Madrid, Spain, 12 June 2013: New data presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism show that apremilast administered to patients with psoriatic arthritis continues to demonstrate meaningful clinical responses beyond 24 weeks. For patients who completed 52 weeks of the study, up to 65% achieved ACR20* response rates. Also, apremilast continued to be well tolerated with an acceptable longer-term safety profile.
Apremilast is a novel, oral small-molecule inhibitor of phosphodiesterase 4 (PDE4). It works as an anti-inflammatory ...
New method successfully scores joint damage in rheumatoid arthritis
2013-06-12
Madrid, Spain, 12 June 2013: A new study presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrates the efficacy of the ARASHI method at evaluating radiographic (X-ray) joint damage in RA.
The study validated the use of ARASHI to assess joint damage in RA, and clarified the pattern of progression of damage during two-year TNF-blocking therapies. In addition to concluding the success of the scoring method, the data also showed that hip and knee joints with pre-existing damage were predisposed to continue destruction, even during ...
RA patients define ideal online tool for physical activity
2013-06-12
Madrid, Spain, 12 June 2013: Results of the first study involving RA patients in the development of an internet-based physical activity intervention were presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism.
These data show that seven categories are crucial for the adoption and maintenance of PA: personal incentives, personal mastering, information adapted to the Rheumatoid Arthritis (RA) condition, peer support, professional coaching, physical environment and resources, and societal support/financial assistance.
RA is a chronic autoimmune ...
LAST 30 PRESS RELEASES:
Stand up to cancer adds new expertise to scientific advisory committee
‘You don’t just throw them in a box.’ Archaeologists, Indigenous scholars call on museums to better care for animal remains
Can AI tell us if those Zoom calls are flowing smoothly? New study gives a thumbs up
The Mount Sinai Hospital ranked among world’s best in Newsweek/Statista rankings
Research shows humans have a long way to go in understanding a dog’s emotions
Discovery: The great whale pee funnel
Team of computer engineers develops AI tool to make genetic research more comprehensive
Are volcanoes behind the oxygen we breathe?
The two faces of liquid water
The Biodiversity Data Journal launches its own data portal on GBIF
Do firefighters face a higher brain cancer risk associated with gene mutations caused by chemical exposure?
Less than half of parents think they have accurate information about bird flu
Common approaches for assessing business impact on biodiversity are powerful, but often insufficient for strategy design
Can a joke make science more trustworthy?
Hiring strategies
Growing consumption of the American eel may lead to it being critically endangered like its European counterpart
KIST develops high-performance sensor based on two-dimensional semiconductor
New study links sleep debt and night shifts to increased infection risk among nurses
Megalodon’s body size and form uncover why certain aquatic vertebrates can achieve gigantism
A longer, sleeker super predator: Megalodon’s true form
Walking, moving more may lower risk of cardiovascular death for women with cancer history
Intracortical neural interfaces: Advancing technologies for freely moving animals
Post-LLM era: New horizons for AI with knowledge, collaboration, and co-evolution
“Sloshing” from celestial collisions solves mystery of how galactic clusters stay hot
Children poisoned by the synthetic opioid, fentanyl, has risen in the U.S. – eight years of national data shows
USC researchers observe mice may have a form of first aid
VUMC to develop AI technology for therapeutic antibody discovery
Unlocking the hidden proteome: The role of coding circular RNA in cancer
Advancing lung cancer treatment: Understanding the differences between LUAD and LUSC
Study reveals widening heart disease disparities in the US
[Press-News.org] Heroin availability increasing across Washington stateNew data reveals rise in drug's use among young adults